TabsDetailsBasic DetailsDate Posted: Thursday, February 1, 2018Status: In progressMedical Product: canagliflozin, canagliflozin/metformin HCl, dapagliflozin propanediol, dapagliflozin/metformin HCl, empagliflozin, empagliflozin/linagliptinDescription: These reports examine the prevalent and incident use of six sodium-glucose cotransporter 2 (SGLT2) inhibitors in the Mini-Sentinel Distributed Database (MSDD). These results were generated using the Mini-Sentinel Distributed Query Tool. Queries were run against the Dispensing Summary Table and distributed on May 18, 2015 to 14 Data Partners; this report includes information from 14 Data Partners. Read More Deliverables (1)Mini-Sentinel Summary Table Report: Prevalent Use of SGLT2 InhibitorsAdditional InformationAdditional DetailsFDA Center: CDERTime Period: 2013 - 2015Study Type: Summary TableAssessment Type: Exploratory AnalysesData Sources: Mini-Sentinel Distributed Database (MSDD)
